trustme.bro/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim
Catch-up vaccination schedules safely mitigate missed doses of infant pneumococcal vaccines.
the verdict
SUPPORTED
the evidence backs this
refutedsupported
the weight of evidence
4 sources for · 0 against

Clinical trials consistently demonstrate that catch-up vaccination schedules for pneumococcal conjugate vaccines are safe, well tolerated, and immunogenic in children who missed initial doses.

Evidence for · 4
A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN).
2022 · cited by 14
Demonstrates that catch-up vaccination with V114 is generally well tolerated and immunogenic in children with incomplete or no prior PCV immunization.
See more details
The analysis

The retrieved literature includes multiple clinical trials (such as papers 5, 7, 8, and 10) explicitly evaluating catch-up vaccination regimens for pneumococcal conjugate vaccines across various age groups. These studies uniformly report that catch-up schedules are safe, well tolerated, and elicit robust immune responses, directly supporting the claim.

More for · 3
A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age
2023 · cited by 4
Shows that PCV13 administered as a catch-up regimen in older infants and children effectively elicits strong immune responses and is well tolerated.
Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study
2015 · cited by 4
Finds that a 2-dose catch-up vaccination with 10-valent pneumococcal conjugate vaccine in the second year of life is safe and immunogenic.
Immunogenicity and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine Among Infants, Toddlers, and Children in Western Burkina Faso: Results From a Clinical Trial of Alternative Immunization Schedules.
2018 · cited by 4
Reports that catch-up and alternative pneumococcal conjugate vaccine schedules exhibit satisfactory safety and immunogenicity profiles.
The paper trail · every fact has a biography
first checked04 Aug 2026
judged → SUPPORTED · 8204 Aug 2026
This receipt carries no identity, shared or not. Sharing publishes your connection to it, not your data.
Check your own claim
Challenge the receipt
trust me, bro: win the argument, pass the class, survive peer review.
This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work · Dispute this receipt